Dyne Therapeutics (NASDAQ:DYN) Stock Rating Upgraded by Wall Street Zen

Dyne Therapeutics (NASDAQ:DYN) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other analysts have also recently weighed in on DYN. Sanford C. Bernstein set a $23.00 price target on Dyne Therapeutics in a research report on Tuesday, December 9th. Lifesci Capital raised Dyne Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 14th. Evercore ISI decreased their target price on Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Monday, December 15th. HC Wainwright increased their price target on Dyne Therapeutics from $46.00 to $60.00 and gave the company a “buy” rating in a report on Monday, December 8th. Finally, Chardan Capital restated a “buy” rating and issued a $38.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, December 9th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.47.

Dyne Therapeutics Stock Performance

DYN stock opened at $19.85 on Friday. The firm has a 50 day moving average of $19.70 and a two-hundred day moving average of $14.54. Dyne Therapeutics has a 12 month low of $6.36 and a 12 month high of $26.22. The company has a market capitalization of $2.83 billion, a price-to-earnings ratio of -5.42 and a beta of 1.30. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.14.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.05. As a group, equities analysts anticipate that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Institutional Trading of Dyne Therapeutics

A number of hedge funds have recently bought and sold shares of DYN. Vanguard Group Inc. increased its holdings in shares of Dyne Therapeutics by 10.5% during the 1st quarter. Vanguard Group Inc. now owns 7,406,344 shares of the company’s stock worth $77,470,000 after purchasing an additional 702,418 shares during the period. Swiss National Bank increased its stake in Dyne Therapeutics by 8.9% during the first quarter. Swiss National Bank now owns 118,300 shares of the company’s stock valued at $1,237,000 after acquiring an additional 9,700 shares during the period. Invesco Ltd. increased its stake in Dyne Therapeutics by 64.4% during the first quarter. Invesco Ltd. now owns 66,293 shares of the company’s stock valued at $693,000 after acquiring an additional 25,970 shares during the period. Nuveen LLC acquired a new position in Dyne Therapeutics in the 1st quarter valued at approximately $2,335,000. Finally, Hsbc Holdings PLC lifted its position in shares of Dyne Therapeutics by 112.6% in the 1st quarter. Hsbc Holdings PLC now owns 28,396 shares of the company’s stock worth $286,000 after acquiring an additional 15,042 shares during the period. 96.68% of the stock is owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.